S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
China Threatens U.S. Defense and Economic Security (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
China Threatens U.S. Defense and Economic Security (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
China Threatens U.S. Defense and Economic Security (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
China Threatens U.S. Defense and Economic Security (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
China Threatens U.S. Defense and Economic Security (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
China Threatens U.S. Defense and Economic Security (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
China Threatens U.S. Defense and Economic Security (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
China Threatens U.S. Defense and Economic Security (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
NASDAQ:RNA

Avidity Biosciences - RNA Stock Forecast, Price & News

$10.06
-1.12 (-10.02%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.89
$11.34
50-Day Range
$11.11
$16.72
52-Week Range
$9.89
$27.00
Volume
1.04 million shs
Average Volume
376,500 shs
Market Capitalization
$547.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50

Avidity Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.17 Rating Score
Upside/​Downside
292.6% Upside
$39.50 Price Target
Short Interest
Bearish
12.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.30) to ($3.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

930th out of 1,023 stocks

Pharmaceutical Preparations Industry

452nd out of 501 stocks

RNA stock logo

About Avidity Biosciences (NASDAQ:RNA) Stock

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Stock News Headlines

What 4 Analyst Ratings Have To Say About Avidity Biosciences
See More Headlines
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Company Calendar

Last Earnings
11/09/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.50
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+292.6%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-118,010,000.00
Net Margins
-1,950.91%
Pretax Margin
-1,950.91%

Debt

Sales & Book Value

Annual Sales
$9.33 million
Book Value
$8.13 per share

Miscellaneous

Free Float
50,868,000
Market Cap
$547.90 million
Optionable
Not Optionable
Beta
0.71

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 53)
    Ph.D., Co-Founder & Chairman
    Comp: $65k
  • Ms. Sarah Boyce (Age 50)
    Pres, CEO & Director
    Comp: $1M
  • Mr. Michael F. MacLean (Age 56)
    Chief Financial & Bus. Officer
    Comp: $650.38k
  • Dr. W. Michael Flanagan Ph.D. (Age 60)
    Chief Technical Officer
    Comp: $1M
  • Dr. Arthur A. Levin Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $662.86k
  • Prof. Mark E. Davis
    Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D. (Age 72)
    Scientific Founder & Member of Scientific Advisory Board
  • Ms. Kathleen Gallagher
    Sr. VP of Corp. Communications & Investor Relations
  • Dr. John W. Wallen III (Age 64)
    VP of Intellectual Property, Gen. Counsel & Sec.
  • Ms. Teresa McCarthy
    Chief HR Officer













RNA Stock - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares.
View RNA analyst ratings
or view top-rated stocks.

What is Avidity Biosciences' stock price forecast for 2023?

6 equities research analysts have issued 1-year price targets for Avidity Biosciences' stock. Their RNA share price forecasts range from $27.00 to $59.00. On average, they anticipate the company's stock price to reach $39.50 in the next twelve months. This suggests a possible upside of 292.6% from the stock's current price.
View analysts price targets for RNA
or view top-rated stocks among Wall Street analysts.

How have RNA shares performed in 2022?

Avidity Biosciences' stock was trading at $23.77 at the beginning of 2022. Since then, RNA stock has decreased by 57.7% and is now trading at $10.06.
View the best growth stocks for 2022 here
.

Are investors shorting Avidity Biosciences?

Avidity Biosciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 7,030,000 shares, an increase of 26.7% from the October 31st total of 5,550,000 shares. Based on an average trading volume of 533,200 shares, the days-to-cover ratio is presently 13.2 days.
View Avidity Biosciences' Short Interest
.

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RNA earnings forecast
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.68) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.68). The biotechnology company earned $2.16 million during the quarter, compared to the consensus estimate of $1.50 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 42.97% and a negative net margin of 1,950.91%.

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.49%), Price T Rowe Associates Inc. MD (9.49%), BlackRock Inc. (7.57%), EcoR1 Capital LLC (5.32%), Vanguard Group Inc. (4.95%) and Federated Hermes Inc. (4.55%). Insiders that own company stock include Arthur A Levin, Rtw Investments, Lp and Sarah Boyce.
View institutional ownership trends
.

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $10.06.

How much money does Avidity Biosciences make?

Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $547.90 million and generates $9.33 million in revenue each year. The biotechnology company earns $-118,010,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis.

How many employees does Avidity Biosciences have?

The company employs 125 workers across the globe.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for the company is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at amy@juniper-point.com.

This page (NASDAQ:RNA) was last updated on 12/7/2022 by MarketBeat.com Staff